Lower extremity vein graft failure: A translational approach

Vascular Medicine

Volumn 13, Issue 1, 2008, Pages 63-74

  Owens, Christopher D ^a   Ho, Karen J ^a   Conte, Michael S ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Lower extremity vein graft disease; Lower extremity vein grafting; Peripheral arterial disease; Vein graft adaptation

Indexed keywords

EDIFOLIGIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; OLIGODEOXYNUCLEOTIDE; TRANSCRIPTION FACTOR E2F;

ARTERY DISEASE; BIOMECHANICS; BYPASS SURGERY; CLINICAL TRIAL; DIABETES MELLITUS; ECHOGRAPHY; GRAFT FAILURE; GRAFT OCCLUSION; HUMAN; KIDNEY DISEASE; LEG ISCHEMIA; LEG REVASCULARIZATION; LEG VEIN; LIMB SALVAGE; NONHUMAN; PHYSICIAN ATTITUDE; POPULATION RESEARCH; PRIORITY JOURNAL; PULSE WAVE; REVIEW; RISK FACTOR; SMOOTH MUSCLE FIBER; VEIN GRAFT; VEIN GRAFT DISEASE;

ANIMALS; GRAFT OCCLUSION, VASCULAR; GRAFT SURVIVAL; HEMODYNAMICS; HUMANS; HYPERPLASIA; LOWER EXTREMITY; PERIPHERAL VASCULAR DISEASES; STRESS, MECHANICAL; TREATMENT FAILURE; VASCULAR SURGICAL PROCEDURES; VEINS; WOUND HEALING;

EID: 42649109332     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X07083432     Document Type: Review

References (84)

1. Mannick, JA. Remembrance of things past - New England surgeons and infrainguinal reconstruction. J Vasc Surg 1996; 24: 1-5.
2. Kunlin, J. [Long vein transplantation in treatment of ischemia caused by arteritis.] Rev Chir 1951; 70: 206-235.
3. Pomposelli, FB, Kansal, N, Hamdan, AD, et al. A decade of experience with dorsalis pedis artery bypass: analysis of outcome in more than 1000 cases. J Vasc Surg 2003; 37: 307-315.
4. Taylor, LM, Porter, JM. Clinical and anatomic considerations for surgery in femoropopliteal disease and the results of surgery. Circulation 1991; 83 (2 suppl): I63-I69.
5. Belkin, M, Whittemore, AD. Infrainguinal bypass. In: RB Rutherford (ed). Vascular surgery, 5th edition. WB Saunders Company, 2000: 998-1018.
6. Nguyen, LL, Lipsitz, SR, Bandyk, DF, et al. Resource utilization in the treatment of critical limb ischemia: the effect of tissue loss, comorbidities, and graft-related events. J Vasc Surg 2006; 44: 971-975; discussion 975-76.
7. Nguyen, LL, Moneta, GL, Conte, MS, Bandyk, DF, Clowes, AW, Seely, BL. Prospective multicenter study of quality of life before and after lower extremity vein bypass in 1404 patients with critical limb ischemia. J Vasc Surg 2006; 44: 977-983; discussion 983-84.
8. Mills, JL, Fujitani, RM, Taylor, SM. The characteristics and anatomic distribution of lesions that cause reversed vein graft failure: a five-year prospective study. J Vasc Surg 1993; 17: 195-204; discussion 204-206.
9. Davies, MG, Hagen, PO. Pathophysiology of vein graft failure: a review. Eur J Vasc Endovasc Surg 1995; 9: 7-18.
10. Towne, JB, Schmitt, DD, Seabrook, GR, Bandyk, DF. The effect of vein diameter on patency of in situ grafts. J Cardiovasc Surg (Torino) 1991; 32: 192-196.
11. Idu, MM, Buth, J, Hop, WC, Cuypers, P, van de Pavoordt, ED, Tordoir, JM. Factors influencing the development of vein-graft stenoses and their significance for clinical management. Eur J Vasc Endovasc Surg 1999; 17: 15-21.
12. Leather, RP, Shah, DM, Chang, BB, Kaufman, JL. Resurrection of the in situ saphenous vein bypass. 1000 cases later. Ann Surg 1988; 208: 435-442.
13. Fogle, MA, Whittemore, AD, Couch, NP, Mannick, JA. A comparison of in situ and reversed saphenous vein grafts for infrainguinal reconstruction. J Vasc Surg 1987; 5: 46-52.
14. Belkin, M, Knox, J, Donaldson, MC, Mannick, JA, Wbittemore, AD. Infrainguinal arterial reconstruction with nonreversed greater saphenous vein. J Vasc Surg 1996; 24: 957-962.
15. Idu, MM, Blankenstein, JD, de Gier, P, Truyen, E, Buth, J. Impact of a color-flow duplex surveillance program on infrainguinal vein graft patency: a five-year experience. J Vasc Surg 1993; 17: 42-52; discussion 52-53.
16. Mills, JL, Wixon, CL, James, DC, Devine, J, Westerband, A, Hughes, JD. The natural history of intermediate and critical vein graft stenoses: recommendations for continued surveillance or repair. J Vasc Surg 2001; 33: 273-278; discussion 278-80.
17. Bandyk, DF, Schmitt, DD, Seabrook, GR, Adams, MB, Towne, JB. Monitoring functional patency of in situ saphenous vein bypasses: the impact of a surveillance protocol and elective revision. J Vasc Surg 1989; 9: 286-296.
18. Lundell, A, Lindblad, B, Bergqvist, D, Hansen, F. Femoropopliteal-crural graft patency is improved by an intensive surveillance program: a prospective randomized study. J Vasc Surg 1995; 21: 26-33; discussion 33-34.
19. Nguyen, LL, Conte, MS, Menard, MT, et al. Infrainguinal vein bypass graft revision: factors affecting long-term outcome. J Vasc Surg 2004; 40: 916-923.
20. Rutherford, RB, Baker, JD, Ernst, C, et al. Recommended standards for reports dealing with lower extremity ischemia: revised version. J Vasc Surg 1997; 26: 517-538.
21. Conte, MS, Belkin, M, Upchurch, GR, Mannick, JA, Whittemore, AD, Donaldson, MC. Impact of increasing comorbidity on infrainguinal reconstruction: a 20-year perspective. Ann Surg 2001; 233: 445-452.
22. Conte, MS, Bandyk, DF, Clowes, AW, et al. Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery. J Vasc Surg 2006; 43: 742-751; discussion 751.
23. Alexander, JH, Hafley, G, Harrington, RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial. JAMA 2005; 294: 2446-2454.
24. Owens, CD, Ho, KJ, Kim, S, et al. Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg 2007; 45: 944-952.
25. Owens, CD, Ridker, PM, Belkin, M, et al. Elevated C-reactive protein levels are associated with postoperative events in patients undergoing lower extremity vein bypass surgery. J Vasc Surg 2007; 45: 2-9; discussion 9.
26. Fortmann, SP, Ford, E, Criqui, MH, et al. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: report from the population science discussion group. Circulation 2004; 110: e554-59.
27. Abbott, RD, Brand, FN, Kannel, WB. Epidemiology of some peripheral arterial findings in diabetic men and women: experiences from the Framingham Study. Am J Med 1990; 88: 376-381.
28. Narayan, KM, Boyle, JP, Thompson, TJ, Sorensen, SW, Williamson, DF. Lifetime risk for diabetes mellitus in the United States. JAMA 2003; 290: 1884-1890.
29. Grundy, SM, Brewer, HB, Cleeman, JI, Smith, SC, Lenfant, C. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004; 109: 433-438.
30. Creager, MA, Luscher, TF, Cosentino, F, Beckman, JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 2003; 108: 1527-1532.
31. Yilmaz, MB, Guray, U, Guray, Y, et al. Metabolic syndrome negatively impacts early patency of saphenous vein grafts. Coron Artery Dis 2006; 17: 41-44.
32. Thompson, DAW. On growth and form. The complete revised edition. Dover Publications, Inc., 1942.
33. Rodbard, S. Vascular caliber. Cardiology 1975; 60: 4-49.
34. Murray, CD. The physiological principle of minimum work: I. The vascular system and the cost of blood volume. Proc Natl Acad Sci U S A 1926; 12: 207-214.
35. Langille, BL, O'Donnell, F. Reductions in arterial diameter produced by chronic decreases in blood flow are endothelium-dependent. Science 1986; 231: 405-407.
36. Ignarro, LJ, Buga, GM, Wood, KS, Byrns, RE, Chaudhuri, G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci U S A 1987; 84: 9265-9269.
37. Zarins, CK, Zatina, MA, Giddens, DP, Ku, DN, Glagov, S. Shear stress regulation of artery lumen diameter in experimental atherogenesis. J Vasc Surg 1987; 5: 413-420.
38. Glagov, S, Weisenberg, E, Zarins, CK, Stankunavicius, R, Kolettis, GJ. Compensatory enlargement of human atherosclerotic coronary arteries. N Engl J Med 1987; 316: 1371-1375.
39. Mintz, GS, Popma, JJ, Pichard, AD, et al. Arterial remodeling after coronary angioplasty: a serial intravascular ultrasound study. Circulation 1996; 94: 35-43.
40. Lafont, A, Guzman, LA, Whitlow, PL, Goormastic, M, Cornhill, JF, Chisolm, GM. Restenoses after experimental angioplasty. Intimal, medial, and adventitial changes associated with constrictive remodeling. Circ Res 1995; 76: 996-1002.
41. Losordo, DW, Rosenfield, K, Kaufman, J, Pieczek, A, Isner, JM. Focal compensatory enlargement of human arteries in response to progressive atherosclerosis. In vivo documentation using intravascular ultrasound. Circulation 1994; 89: 2570-2577.
42. Post, MJ, Borst, C, Kuntz, RE. The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig. s 1994; 89: 2816-2821.
43. Gibbons, GH, Dzau, VJ. The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431-1438.
44. Milroy, CM, Scott, DJ, Beard, JD, Horrocks, M, Bradfield, JW. Histological appearances of the long saphenous vein. J Pathol 1989; 159: 311-316.
45. De Mey, JG, Vanhoutte, PM. Heterogeneous behavior of the canine arterial and venous wall. Importance of the endothelium. Circ Res 1982; 51: 439-447.
46. Luscher, TF, Diederich, D, Siebenmann, R, et al. Difference between endothelium-dependent relaxation in arterial and in venous coronary bypass grafts. N Engl J Med 1988; 319: 462-467.
47. Liu, ZG, Ge, ZD, He, GW. Difference in endothelium-derived hyperpolarizing factor-mediated hyperpolarization and nitric oxide release between human internal mammary artery and saphenous vein. Circulation 2000; 102: III296-301.
48. Nishioka, H, Kitamura, S, Kameda, Y, Taniguchi, S, Kawata, T, Mizuguchi, K. Difference in acetylcholine-induced nitric oxide release of arterial and venous grafts in patients after coronary bypass operations. J Thorac Cardiovasc Surg 1998; 116: 454-459.
49. Yang, Z, Oemar, BS, Carrel, T, Kipfer, B, Julmy, F, Luscher, TF. Different proliferative properties of smooth muscle cells of human arterial and venous bypass vessels: role of PDGF receptors, mitogen-activated protein kinase, and cyclin-dependent kinase inhibitors. Circulation 1998; 97: 181-187.
50. Deng, DX, Spin, JM, Tsalenko, A, et al. Molecular signatures determining coronary artery and saphenous vein smooth muscle cell phenotypes: distinct responses to stimuli. Arterioscler Thromb Vasc Biol 2006; 26: 1058-1065.
51. Kim, AY, Walinsky, PL, Kolodgie, FD, et al. Early loss of thrombomodulin expression impairs vein graft thromboresistance: implications for vein graft failure. Circ Res 2002; 90: 205-212.
52. Henderson, VJ, Cohen, RG, Mitchell, RS, Kosek, JC, Miller, DC. Biochemical (functional) adaptation of 'arterialized' vein grafts. Ann Surg 1986; 203: 339-345.
53. Chaikhouni, A, Crawford, FA, Kochel, PJ, Olanoff, LS, Halushka, PV. Human internal mammary artery produces more prostacyclin than saphenous vein. J Thorac Cardiovasc Surg 1986; 88-91.
54. Wesly, RL, Vaishnav, RN, Fuchs, JC, Patel, DJ, Greenfield, JC. Static linear and nonlinear elastic properties of normal and arterialized venous tissue in dog and man. Circ Res 1975; 37: 509-520.
55. Cox, JL, Chiasson, DA, Gotlieb, AI. Stranger in a strange land: the pathogenesis of saphenous vein graft stenoses with emphasis on structural and functional differences between veins and arteries. Prog Cardiovasc Dis 1991; 34: 45-68.
56. Davies, AH, Magee, TR, Baird, RN, Sheffield, E, Horrocks, M. Pre-bypass morphological changes in vein grafts. Eur J Vasc Surg 1993; 7: 642-647.
57. Owens, CD, Wake, N, Jacot, JG, et al. Early biomechanical changes in lower extremity vein grafts - distinct temporal phases of remodeling and wall stiffness. J Vasc Surg 2006; 44: 740-746.
58. Jacot, JG, Abdullah, I, Belkin, M, et al. Early adaptation of human lower extremity vein grafts: wall stiffness changes accompany geometric remodeling. J Vasc Surg 2004; 39: 547-555.
59. Owens, CD, Wake, N, Schanzer, A, et al. Early remodeling of lower extremity vein grafts: modulation of hemodynamic adaptation by systemic inflammation. Research Initiatives in Vascular Disease Conference. Washington, DC, March 30, 2007. J Vasc Surg 2008 (in press).
60. Leotta, DF, Primozich, JF, Beach, KW, Bergelin, RO, Zierler, RE, Strandness, DE. Remodeling in peripheral vein graft revisions: serial study with three-dimensional ultrasound imaging. J Vasc Surg 2003; 37: 798-807.
61. Fillinger, MF, Cronenwett, JL, Besso, S, Walsh, DB, Zwolak, RM. Vein adaptation to the hemodynamic environment of infrainguinal grafts. J Vasc Surg 1994; 19: 970-978; discussion 978-79.
62. Cheshire, NJ, Wolfe, JH, Barradas, MA, Chambler, AW, Mikhailidis, DP. Smoking and plasma fibrinogen, lipoprotein (a) and serotonin are markers for postoperative infrainguinal graft stenoses. Eur J Vasc Endovasc Surg 1996; 11: 479-486.
63. Hicks, RC, Ellis, M, Mir-Hasseine, R, et al. The influence of fibrinogen concentration on the development of vein graft stenoses. Eur J Vasc Endovasc Surg 1995; 9: 415-420.
64. Irvine, C, Wilson, YG, Currie, IC, et al. Hyperhomocysteinaemia is a risk factor for vein graft stenoses. Eur J Vasc Endovasc Surg 1996; 12: 304-309.
65. Lippi, G, Veraldi, GF, Dorucci, V, et al. Usefulness of lipids, lipoprotein(a) and fibrinogen measurements in identifying subjects at risk of occlusive complications following vascular and endovascular surgery. Scand J Clin Lab Invest 1998; 58: 497-504.
66. Laxdal, E, Eide, GE, Wirsching, J, et al. Homocysteine levels, haemostatic risk factors and patency rates after endovascular treatment of the above-knee femoro-popliteal artery. Eur J Vasc Endovasc Surg 2004; 28: 410-417.
67. De Borst, GJ, Tangelder, MJ, Algra, A, et al. The influence of hyperhomocysteinemia on graft patency after infrainguinal bypass surgery in the Dutch BOA Study. J Vasc Surg 2002; 36: 336-340.
68. Chew, DK, Nguyen, LL, Owens, CD, et al. Comparative analysis of autogenous infrainguinal bypass grafts in African Americans and Caucasians: the association of race with graft function and limb salvage. J Vasc Surg 2005; 42: 695-701.
69. Mann, MJ, Whittemore, AD, Donaldson, MC, et al. Ex-vivo gene therapy of human vascular bypass grafts with E2F decoy: the PREVENT single-centre, randomised, controlled trial. Lancet 1999; 354: 1493-1498.
70. Kalra, M, Miller, VM. Early remodeling of saphenous vein grafts: proliferation, migration and apoptosis of adventitial and medial cells occur simultaneously with changes in graft diameter and blood flow. J Vasc Res 2000; 37: 576-584.
71. Kalra, M, Jost, CJ, Severson, SR, Miller, VM. Adventitial versus intimal liposome-mediated ex vivo transfection of canine saphenous vein grafts with endothelial nitric oxide synthase gene. J Vasc Surg 2000; 32: 1190-1200.
72. Mannion, JD, Ormont, ML, Shi, Y, et al. Saphenous vein graft protection: effects of c-myc antisense. J Thorac Cardiovasc Surg 1998; 115: 152-161.
73. Hu, Y, Mayr, M, Metzler, B, Erdel, M, Davison, F, Xu, Q. Both donor and recipient origins of smooth muscle cells in vein graft atherosclerotic lesions. Circ Res 2002; 91: e13-e20.
74. Zalewski, A, Shi, Y, Johnson, AG. Diverse origin of intimal cells: smooth muscle cells, myofibroblasts, fibroblasts, and beyond? Circ Res 2002; 91: 652-655.
75. Shi, Y, O'Brien, JE, Mannion, JD, et al. Remodeling of autologous saphenous vein grafts. The role of perivascular myofibroblasts. Circulation 1997; 95: 2684-2693.
76. Zhang, L, Freedman, NJ, Brian, L, Peppel, K. Graft-extrinsic cells predominate in vein graft arterialization. Arterioscler Thromb Vasc Biol 2004; 24: 470-476.
77. Shi, Y, O'Brien, JE, Ala-Kokko, L, Chung, W, Mannion, JD, Zalewski, A. Origin of extracellular matrix synthesis during coronary repair. Circulation 1997; 95: 997-1006.
78. Schachner, T, Laufer, G, Bonatti, J. In vivo (animal) models of vein graft disease. Eur J Cardiothorac Surg 2006; 30: 451-463.
79. Prasad, K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006; 24: 33-50.
80. Van de Ree, MA, Huisman, MV, Princen, HM, Meinders, AE, Kluft, C. Strong decrease of high sensitivity C-reactive protein with high-dose atorvastatin in patients with type 2 diabetes mellitus. Atherosclerosis 2003; 166: 129-135.
81. Nissen, SE, Tuzcu, EM, Schoenhagen, P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-1080.
82. Ballantyne, CM, Houri, J, Notarbartolo, A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003; 107: 2409-2415.
83. Abbruzzese, TA, Havens, J, Belkin, M, et al. Statin therapy is associated with improved patency of autogenous infrainguinal bypass grafts. J Vasc Surg 2004; 39: 1178-1185.
84. Conte, MS, Mann, MJ, Simosa, HF, Rhynhart, KK, Mulligan, RC. Genetic interventions for vein bypass graft disease: a review. J Vasc Surg 2002; 36: 1040-1052.